CoChat

A Sativex®‐like combination of phytocannabinoids as a disease‐modifying therapy in a viral model of multiple sclerosis

Open access
Feliú, A, Moreno‐Martet, M, Mecha, M, Carrillo‐Salinas, F J, de Lago, E, Fernández‐Ruiz, J, Guaza, C · 2015 · British Journal of Pharmacology
Cited by 70

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background and Purpose: S ativex® is an oromucosal spray, containing equivalent amounts of Δ 9‐tetrahydrocannabinol (Δ 9‐THC) and cannabidiol (CBD)‐botanical drug substance (BDS), which has been approved for the treatment of spasticity and pain associated to multiple sclerosis (MS). In this study, we investigated whether S ativex may also serve as a disease‐modifying agent in the T heiler's murine encephalomyelitis virus‐induced demyelinating disease model of MS. Experimental Approach: A S ativex‐like combination of phytocannabinoids and each phytocannabinoid alone were administered to mice once they had established MS‐like symptoms. Motor activity and the putative targets of these cannabinoids were assessed to evaluate therapeutic efficacy. The accumulation of chondroitin sulfate proteoglycans (CSPGs) and astrogliosis were assessed in the spinal cord and the effect of S ativex on CSPGs production was evaluated in astrocyte cultures. Key Results: Sativex improved motor activity – reduced CNS infiltrates, microglial activity, axonal damage – and restored myelin morphology. Similarly, we found weaker vascular cell adhesion molecule‐1 staining and IL‐1β gene expression but an up‐regulation of arginase‐1. The astrogliosis and accumulation of CSPGs in the spinal cord in vehicle‐infected animals were decreased by S ativex, as was the synthesis and release of CSPGs by astrocytes in culture. We found that CBD‐BDS alone alleviated motor deterioration to a similar extent as S ativex, acting through PPAR γ receptors whereas Δ 9‐THC‐BDS produced weaker effects, acting through CB2 and primarily CB1 receptors. Conclusions and Implications: The data support the therapeutic potential of S ativex to slow MS progression and its relevance in CNS repair.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.13159

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

Metadata

Authors
Feliú, A., Moreno‐Martet, M., Mecha, M., Carrillo‐Salinas, F. J., de Lago, E., Fernández‐Ruiz, J., & Guaza, C.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2015-05-20
Volume
172
Issue
14
Pages
3579-3595
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1833126618
Cited by
70
References
10
FWCI
3.81
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.